{"transactions":[{"id":747949,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:35:07.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001609805-26-000003","document":"form4-06052026_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980526000003/form4-06052026_090603.xml","form_type":"4"}},{"id":1016812,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":155262,"price":17.75,"value":2755900.5,"ownership":{"direct":false,"nature":"By Pontifax Late Stage Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016811,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":1226412,"price":17.75,"value":21768813.0,"ownership":{"direct":false,"nature":"By Pontifax (China) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016810,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":1121045,"price":17.75,"value":19898548.75,"ownership":{"direct":false,"nature":"By Pontifax (Cayman) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016809,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":2284612,"price":17.75,"value":40551863.0,"ownership":{"direct":false,"nature":"By Pontifax (Israel) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1039355,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T20:15:05.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":10000000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":411681},"source":{"system":"sec-edgar","filing":"0001609805-25-000006","document":"form4-09162025_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980525000006/form4-09162025_040901.xml","form_type":"4"}},{"id":1039354,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:05.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":15,"value":15000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":1411681,"source":{"system":"sec-edgar","filing":"0001609805-25-000006","document":"form4-09162025_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980525000006/form4-09162025_040901.xml","form_type":"4"}},{"id":1039353,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:05.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":411681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":411681,"source":{"system":"sec-edgar","filing":"0001609805-25-000006","document":"form4-09162025_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000160980525000006/form4-09162025_040901.xml","form_type":"4"}},{"id":1041593,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:14.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024447","document":"form4-09122025_100911.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024447/form4-09122025_100911.xml","form_type":"4"}},{"id":1119149,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:15:15.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10500,"derivative":{"exercise_price":14.82,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001415889-25-015976","document":"form4-06062025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000141588925015976/form4-06062025_040610.xml","form_type":"4"}},{"id":1119148,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:15:15.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001415889-25-015976","document":"form4-06062025_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000141588925015976/form4-06062025_040610.xml","form_type":"4"}},{"id":1494763,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T20:15:17.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":46.31,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-015154","document":"form4-06032024_040613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000141588924015154/form4-06032024_040613.xml","form_type":"4"}},{"id":1861763,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T20:44:14.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":48.79,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-035457","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919123035457/doc4.xml","form_type":"4"}},{"id":1987045,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-02-28T17:29:13.000Z","date":"2022-06-06","kind":"exercise","acquired":false,"shares":1030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2015-09-01","expiration_date":"2022-09-01","underlying":"Ordinary Shares","underlying_shares":1030},"source":{"system":"sec-edgar","filing":"0001437749-23-004870","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004870/rdgdoc.xml","form_type":"4/A","original_submission_date":"2022-08-25"}},{"id":1987044,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-02-28T17:29:13.000Z","date":"2022-06-06","kind":"exercise","acquired":true,"shares":1030,"price":5,"value":5150.0,"ownership":{"direct":false,"nature":"Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd."},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares."}],"balance_after":1434958,"source":{"system":"sec-edgar","filing":"0001437749-23-004870","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004870/rdgdoc.xml","form_type":"4/A","original_submission_date":"2022-08-25"}},{"id":1987043,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-02-28T17:23:21.000Z","date":"2022-10-21","kind":"exercise","acquired":false,"shares":15276,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5.94,"exercise_date":"2018-12-27","expiration_date":"2022-12-27","underlying":"Ordinary Shares","underlying_shares":15276},"source":{"system":"sec-edgar","filing":"0001437749-23-004868","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004868/rdgdoc.xml","form_type":"4/A","original_submission_date":"2022-10-25"}},{"id":1987042,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-02-28T17:23:21.000Z","date":"2022-10-21","kind":"exercise","acquired":false,"shares":32723,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax (Israel) III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5.94,"exercise_date":"2018-12-27","expiration_date":"2022-12-27","underlying":"Ordinary Shares","underlying_shares":32723},"source":{"system":"sec-edgar","filing":"0001437749-23-004868","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004868/rdgdoc.xml","form_type":"4/A","original_submission_date":"2022-10-25"}},{"id":1987041,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-02-28T17:23:21.000Z","date":"2022-10-21","kind":"exercise","acquired":true,"shares":47999,"price":5.94,"value":285114.06,"ownership":{"direct":false,"nature":"Managing\nmember of\nentities\naffiliated with\nPontifax\nManagement\nIII G.P.\n(2011) Ltd"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On October 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,481,927 shares of securities beneficially owned following reported transaction instead of 1,485,168 shares."}],"balance_after":1485168,"source":{"system":"sec-edgar","filing":"0001437749-23-004868","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004868/rdgdoc.xml","form_type":"4/A","original_submission_date":"2022-10-25"}},{"id":1987040,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-02-28T17:21:59.000Z","date":"2022-06-16","kind":"exercise","acquired":false,"shares":2211,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax (Israel) III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2015-09-01","expiration_date":"2022-09-01","underlying":"Ordinary Shares","underlying_shares":2211},"source":{"system":"sec-edgar","filing":"0001437749-23-004866","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004866/rdgdoc.xml","form_type":"4"}},{"id":1987039,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2023-02-28T17:21:59.000Z","date":"2022-06-16","kind":"exercise","acquired":true,"shares":2211,"price":5,"value":11055.0,"ownership":{"direct":false,"nature":"Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd."},"balance_after":1437169,"source":{"system":"sec-edgar","filing":"0001437749-23-004866","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774923004866/rdgdoc.xml","form_type":"4"}},{"id":2101150,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T21:40:01.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1914,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":1914},"source":{"system":"sec-edgar","filing":"0001209191-22-059052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122059052/doc4.xml","form_type":"4"}},{"id":2101149,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T21:40:01.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1723,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":1723},"source":{"system":"sec-edgar","filing":"0001209191-22-059052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122059052/doc4.xml","form_type":"4"}},{"id":2101148,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T21:40:01.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":3539,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":3539},"source":{"system":"sec-edgar","filing":"0001209191-22-059052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122059052/doc4.xml","form_type":"4"}},{"id":2101147,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:40:01.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1914,"price":0.0001,"value":0.1914,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by China IV. Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1226412,"source":{"system":"sec-edgar","filing":"0001209191-22-059052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122059052/doc4.xml","form_type":"4"}},{"id":2101146,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:40:01.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1723,"price":0.0001,"value":0.1723,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1121045,"source":{"system":"sec-edgar","filing":"0001209191-22-059052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122059052/doc4.xml","form_type":"4"}},{"id":2101145,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:40:01.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":3539,"price":0.0001,"value":0.3539,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2284612,"source":{"system":"sec-edgar","filing":"0001209191-22-059052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122059052/doc4.xml","form_type":"4"}},{"id":2132342,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-10-25T20:57:00.000Z","date":"2022-10-21","kind":"exercise","acquired":false,"shares":15276,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5.94,"exercise_date":"2018-12-27","expiration_date":"2022-12-27","underlying":"Ordinary Shares","underlying_shares":15276},"source":{"system":"sec-edgar","filing":"0001437749-22-024711","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922024711/rdgdoc.xml","form_type":"4"}},{"id":2132341,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-10-25T20:57:00.000Z","date":"2022-10-21","kind":"exercise","acquired":false,"shares":32723,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax (Israel) III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5.94,"exercise_date":"2018-12-27","expiration_date":"2022-12-27","underlying":"Ordinary Shares","underlying_shares":32723},"source":{"system":"sec-edgar","filing":"0001437749-22-024711","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922024711/rdgdoc.xml","form_type":"4"}},{"id":2132340,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-10-25T20:57:00.000Z","date":"2022-10-21","kind":"exercise","acquired":true,"shares":47999,"price":5.94,"value":285114.06,"ownership":{"direct":false,"nature":"Managing\nmember of\nentities\naffiliated with\nPontifax\nManagement\nIII G.P.\n(2011) Ltd"},"balance_after":1481927,"source":{"system":"sec-edgar","filing":"0001437749-22-024711","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922024711/rdgdoc.xml","form_type":"4"}},{"id":2173936,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-08-25T19:25:35.000Z","date":"2022-06-06","kind":"exercise","acquired":false,"shares":1030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2015-09-01","expiration_date":"2022-08-31","underlying":"Ordinary Shares","underlying_shares":1030},"source":{"system":"sec-edgar","filing":"0001437749-22-021338","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922021338/rdgdoc.xml","form_type":"4"}},{"id":2173935,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Ordinary Shares","published_at":"2022-08-25T19:25:35.000Z","date":"2022-06-06","kind":"exercise","acquired":true,"shares":1030,"price":5,"value":5150.0,"ownership":{"direct":false,"nature":"Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd."},"balance_after":1433928,"source":{"system":"sec-edgar","filing":"0001437749-22-021338","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922021338/rdgdoc.xml","form_type":"4"}},{"id":2228487,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:26:16.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072179","document":"tm2218714-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072179/tm2218714-3_4seq1.xml","form_type":"4"}},{"id":2235928,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T19:36:16.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":3183,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":3183,"derivative":{"exercise_price":7.06,"expiration_date":"2032-06-08","underlying":"Ordinary Shares","underlying_shares":3183},"source":{"system":"sec-edgar","filing":"0001437749-22-014770","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922014770/rdgdoc.xml","form_type":"4"}},{"id":2235927,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T19:36:16.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":6817,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Pontifax (Israel) III Limited Partnership"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":6817,"derivative":{"exercise_price":7.06,"expiration_date":"2032-06-08","underlying":"Ordinary Shares","underlying_shares":6817},"source":{"system":"sec-edgar","filing":"0001437749-22-014770","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922014770/rdgdoc.xml","form_type":"4"}},{"id":2243706,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-03T20:30:50.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":32.95,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-22-034054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919122034054/doc4.xml","form_type":"4"}},{"id":2675684,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:46:26.000Z","date":"2021-03-25","kind":"exercise","acquired":false,"shares":1030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021."}],"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2014-07-27","expiration_date":"2021-07-27","underlying":"Ordinary Shares","underlying_shares":1030},"source":{"system":"sec-edgar","filing":"0001209191-21-039137","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039137/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-22"}},{"id":2675683,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-09T17:46:26.000Z","date":"2021-03-25","kind":"exercise","acquired":true,"shares":1030,"price":5,"value":5150.0,"ownership":{"direct":false,"nature":"Managing Partner of entities affiliated with Pontifax Management III G.P. ("},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021."}],"balance_after":1431717,"source":{"system":"sec-edgar","filing":"0001209191-21-039137","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039137/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-22"}},{"id":2675678,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:42:26.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":3183,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":3183,"derivative":{"exercise_price":17.89,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":3183},"source":{"system":"sec-edgar","filing":"0001209191-21-039132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039132/doc4.xml","form_type":"4"}},{"id":2675677,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:42:26.000Z","date":"2021-06-07","kind":"grant","acquired":true,"shares":6817,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Pontifax (Israel) III Limited Partnership"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":6817,"derivative":{"exercise_price":17.89,"expiration_date":"2031-06-06","underlying":"Common Stock","underlying_shares":6817},"source":{"system":"sec-edgar","filing":"0001209191-21-039132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039132/doc4.xml","form_type":"4"}},{"id":2675676,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-09T17:42:26.000Z","date":"2021-03-25","kind":"exercise","acquired":false,"shares":2211,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Pontifax (Israel) III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2014-07-27","expiration_date":"2021-07-27","underlying":"Common Stock","underlying_shares":2211},"source":{"system":"sec-edgar","filing":"0001209191-21-039132","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039132/doc4.xml","form_type":"4"}},{"id":2675675,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-06-09T17:42:26.000Z","date":"2021-03-25","kind":"exercise","acquired":true,"shares":2211,"price":5,"value":11055.0,"ownership":{"direct":false,"nature":"Managing Partner of entities affiliated with Pontifax Management III G.P."},"balance_after":1433928,"source":{"system":"sec-edgar","filing":"0001209191-21-039132","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121039132/doc4.xml","form_type":"4"}},{"id":2682326,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-03T21:34:21.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":51.48,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-21-037802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919121037802/doc4.xml","form_type":"4"}},{"id":2703642,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:50.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002614","document":"form4-05202021_040537.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002614/form4-05202021_040537.xml","form_type":"4"}},{"id":2710680,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:02:18.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":592592,"price":1.35,"value":799999.2,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd., the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Mr. Nussbaum disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":616592,"source":{"system":"sec-edgar","filing":"0001104659-21-067335","document":"tm2116620d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067335/tm2116620d2_4.xml","form_type":"4"}},{"id":2710679,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:02:18.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1422222,"price":1.35,"value":1919999.7,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1989551,"source":{"system":"sec-edgar","filing":"0001104659-21-067335","document":"tm2116620d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067335/tm2116620d2_4.xml","form_type":"4"}},{"id":2710678,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:02:18.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":2630487,"price":1.35,"value":3551157.45,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":3679797,"source":{"system":"sec-edgar","filing":"0001104659-21-067335","document":"tm2116620d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067335/tm2116620d2_4.xml","form_type":"4"}},{"id":2710677,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:02:18.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1280624,"price":1.35,"value":1728842.4,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. Mr. Nussbaum is a Managing Partner of Management 4. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1791470,"source":{"system":"sec-edgar","filing":"0001104659-21-067335","document":"tm2116620d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067335/tm2116620d2_4.xml","form_type":"4"}},{"id":2742013,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-22T21:18:40.000Z","date":"2021-03-24","kind":"exercise","acquired":false,"shares":1030,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Cayman III Limited Partnership"},"balance_after":0,"derivative":{"exercise_price":5,"exercise_date":"2014-07-27","expiration_date":"2021-07-27","underlying":"Ordinary Shares","underlying_shares":1030},"source":{"system":"sec-edgar","filing":"0001209191-21-027977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121027977/doc4.xml","form_type":"4"}},{"id":2742012,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-22T21:18:40.000Z","date":"2021-03-24","kind":"exercise","acquired":true,"shares":1030,"price":5,"value":5150.0,"ownership":{"direct":false,"nature":"Managing Partner of entities affiliated with Pontifax Management III G.P. ("},"balance_after":1465199,"source":{"system":"sec-edgar","filing":"0001209191-21-027977","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121027977/doc4.xml","form_type":"4"}},{"id":2895484,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-26T17:07:13.000Z","date":"2021-01-22","kind":"disposition_to_issuer","acquired":false,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":16.98,"underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-005410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919121005410/doc4.xml","form_type":"4"}},{"id":2895483,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-26T17:07:13.000Z","date":"2021-01-22","kind":"other","acquired":false,"shares":1576881,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Merger Agreement, these shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive (i) $22.50 per share of common stock, net to the seller in cash, without interest (the \"Closing Amount\"), plus (ii) one contingent value right per share (a \"CVR\"), which shall represent the right to receive certain consideration based on the achievement of net sales milestones."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes (a) 242,141 shares held by Pontifax (Cayman) V L.P., (b) 352,209 shares held by Pontifax (China) V L.P., (c) 906,537 shares held by Pontifax (Israel) V Limited Partnership, and (d) 75,994 shares held by Pontifax Late Stage Fund, L.P. (together, the \"Pontifax Entities\"). Pontifax 5 G.P. L.P.(\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. The Reporting Person is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. The Reporting Person disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-005410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919121005410/doc4.xml","form_type":"4"}},{"id":2973271,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:40:37.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":6000,"price":50,"value":300000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":155262,"source":{"system":"sec-edgar","filing":"0001209191-20-059411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059411/doc4.xml","form_type":"4"}},{"id":2973270,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:40:37.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":14400,"price":50,"value":720000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1228326,"source":{"system":"sec-edgar","filing":"0001209191-20-059411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059411/doc4.xml","form_type":"4"}},{"id":2973269,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:40:37.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":12966,"price":50,"value":648300.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1122768,"source":{"system":"sec-edgar","filing":"0001209191-20-059411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059411/doc4.xml","form_type":"4"}},{"id":2973268,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T16:40:37.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":26634,"price":50,"value":1331700.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2288151,"source":{"system":"sec-edgar","filing":"0001209191-20-059411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726030/000120919120059411/doc4.xml","form_type":"4"}},{"id":3104382,"issuer":{"id":11821,"kind":"organization","name":"Prevail Therapeutics Inc.","symbol":"PRVL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T18:38:46.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 17, 2021 and (ii) the date immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":17000,"derivative":{"exercise_price":16.98,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-20-038058","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714798/000120919120038058/doc4.xml","form_type":"4"}},{"id":3114837,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-10T22:41:24.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in equal quarterly installments over a period of one year."}],"balance_after":10000,"derivative":{"exercise_price":28.24,"expiration_date":"2030-06-07","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-035682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120035682/doc4.xml","form_type":"4"}},{"id":3137696,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:10:19.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":3.39,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-20-001299","document":"form4-05222020_040506.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920001299/form4-05222020_040506.xml","form_type":"4"}},{"id":3177647,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":36858,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36858},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177646,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":79653,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":79653},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177645,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":88460,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":88460},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177644,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":163612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":163612},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177643,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":68654,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68654},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177642,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":91538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":91538},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177641,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":82425,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":82425},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177640,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":169307,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":169307},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177639,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":737226,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737226},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177638,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":663825,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":663825},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177637,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":1363542,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1363542},"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177636,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":43750,"price":16,"value":700000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":149262,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177635,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":105000,"price":16,"value":1680000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1213926,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177634,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":94546,"price":16,"value":1512736.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1109802,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177633,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":194203,"price":16,"value":3107248.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2261517,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177632,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":36858,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":105512,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177631,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":79653,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1108926,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177630,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":88460,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1015256,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177629,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":163612,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2067314,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177628,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":68654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, each of Management 4 and the Reporting Person may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":68654,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177627,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":91538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1029273,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177626,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":82425,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":926796,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177625,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":169307,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1903702,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177624,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":737226,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by China IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":937735,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177623,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":663825,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":844371,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3177622,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:16:14.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":1363542,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. The Reporting Person, a member of the board of directors of the Issuer, is a Managing Partner of Management 4 and, as a result, may be deemed to share voting and investment power with respect to the shares held by Israel IV. Each of Management 4 and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1734395,"source":{"system":"sec-edgar","filing":"0001209191-20-024229","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609805/000120919120024229/doc4.xml","form_type":"4"}},{"id":3310093,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":6.21,"expiration_date":"2029-05-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310092,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.48,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310091,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common sotck subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.1,"expiration_date":"2027-11-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310090,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"other","acquired":false,"shares":8611,"price":20,"value":172220.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 6, 2019, ArQule, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Merck Sharpe & Dohme Corp. (\"MSD\") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD (\"Merger Sub\"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Represents shares of the Issuer held by Pontifax III Management of Fund (2011) Ltd., a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Pontifax III Management Fund (2011) Ltd. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310089,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"other","acquired":false,"shares":36923,"price":20,"value":738460.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 6, 2019, ArQule, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Merck Sharpe & Dohme Corp. (\"MSD\") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD (\"Merger Sub\"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late stage Fund L.P., a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Pontifax Late stage Fund L.P. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310088,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"other","acquired":false,"shares":2088816,"price":20,"value":41776320.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 6, 2019, ArQule, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Merck Sharpe & Dohme Corp. (\"MSD\") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD (\"Merger Sub\"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310087,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"other","acquired":false,"shares":4290550,"price":20,"value":85811000.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 6, 2019, ArQule, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Merck Sharpe & Dohme Corp. (\"MSD\") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD (\"Merger Sub\"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3310086,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-16T15:57:43.000Z","date":"2020-01-16","kind":"other","acquired":false,"shares":2319920,"price":20,"value":46398400.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 6, 2019, ArQule, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Merck Sharpe & Dohme Corp. (\"MSD\") and Argon Merger Sub, Inc., a wholly-owned subsidiary of MSD (\"Merger Sub\"), pursuant to which MSD acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 16, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $20.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-004728","document":"tm203607d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465920004728/tm203607d9_4.xml","form_type":"4"}},{"id":3330626,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"exercise","acquired":false,"shares":400558,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully Vested."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax Late stage Fund L.P., a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Pontifax Late stage Fund L.P. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.75,"expiration_date":"2022-05-08","underlying":"Common Stock","underlying_shares":400558},"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330625,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"exercise","acquired":false,"shares":823632,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully Vested."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.75,"expiration_date":"2022-05-08","underlying":"Common Stock","underlying_shares":823632},"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330624,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrants","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"exercise","acquired":false,"shares":445524,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully Vested."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":1.75,"expiration_date":"2022-05-08","underlying":"Common Stock","underlying_shares":445524},"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330623,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"tax_withholding","acquired":false,"shares":34857,"price":20.11,"value":700974.27,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2088816,"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330622,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"exercise","acquired":true,"shares":400558,"price":1.75,"value":700976.5,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2123673,"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330621,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"tax_withholding","acquired":false,"shares":71674,"price":20.11,"value":1441364.14,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":4290550,"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330620,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"exercise","acquired":true,"shares":823632,"price":1.75,"value":1441356.0,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":4362224,"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}},{"id":3330619,"issuer":{"id":11927,"kind":"organization","name":"ARQULE INC","symbol":"ARQL"},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T20:48:14.000Z","date":"2019-12-24","kind":"tax_withholding","acquired":false,"shares":38770,"price":20.11,"value":779664.7,"ownership":{"direct":false,"nature":"By Pontifax Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (China) IV, L.P. (\"China IV\"), a member of the Pontifax Group. Mr. Nussbaum is a Managing Partner of the Pontifax Group. By virtue of this relationship, Mr. Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by China IV. Mr. Nussbaum disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2319920,"source":{"system":"sec-edgar","filing":"0001104659-19-076530","document":"tm1927513d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1019695/000110465919076530/tm1927513d1_4.xml","form_type":"4"}}],"next_cursor":"2019-12-27T20:48:14.000000Z,3330619"}